Berry Genomics Co., Ltd. is a genomics and life science company that develops and commercializes genetic testing technologies for clinical applications in China. It offers non-invasive prenatal DNA testing, genetic disease testing, tumor detection, technology services, equipment and reagents, laboratory solutions, and big data services. The company also provides scientific research and medical testing services and products, as well as the GENOSi intelligent agent cloud platform and the NovaSeq next-generation sequencing platform. Founded in 1997 and headquartered in Beijing, it serves hospitals, research institutions, universities, and enterprises across Mainland China, Hong Kong, Macau, and Taiwan.
Xinhua Winshare leads media sector with 5 consecutive limit-ups, plans to acquire Sichuan Nationalities Publishing House for 346 million yuan
On September 24, major A-share indices opened lower, while the media sector bucked the trend in early trading. Xinhua Winshare hit its fifth consecutive limit-up, Xinhua Media its fourth, and Topway Video its third, with Guangdong Media and Inner Mongolia Xinhua Distribution also among the top gainers. In news, Xinhua Winshare recently announced plans to use its own funds to acquire the 100% equity stake in Sichuan Nationalities Publishing House held by its controlling shareholder, Sichuan Xinhua Publishing and Distribution Group, for 346 million yuan. The transaction constitutes a related-party transaction but does not constitute a major asset restructuring. On the same day, Bairui Gene debuted on the Beijing Stock Exchange, opening 347.23% higher and rising more than 400% as of press time, with an issue price of 16.77 yuan. The company focuses on the research, production, and sales of biomedical materials and other products. The AI-driven drug discovery concept saw a sudden surge, with Berry Genomics hitting the daily limit-up in a straight line, and BGI Genomics, Rongtai Health, Saili Medical, Sino Biological, and Kingmed Diagnostics following higher. This came after the Ministry of Industry and Information Technology and nine other departments jointly issued the 15th Five-Year Plan for the development of the pharmaceutical industry, which explicitly calls for accelerating the use of artificial intelligence and other new technologies to empower drug research and development. The coal sector fluctuated higher, with Yunnan Coal Energy hitting the daily limit-up, briefly opening, and then sealing the limit-up again. Zhengzhou Coal Mining Machinery, Liaoning Energy, Antai Group, and Shaanxi Heimao followed higher. On September 24, the benchmark price for thermal coal on SunSirs was 989.50 yuan per ton, up 13.02% from 875.50 yuan per ton at the beginning of the month. The robotics concept saw localized movement, with Xiangyang Automobile Bearing hitting the limit-up, and Ningbo Dongli, Wanxiang Qianchao, Nanfang Precision, Sanhua Intelligent Controls, and Tuopu Group following higher. Tesla CEO Elon Musk said in an interview on September 23 that he predicts there will be at least 1 billion humanoid robots within 10 years or less, perhaps 10 billion in the next 15 years, and possibly 100 billion in the next 20 years. The real estate sector fell sharply, with Huali Family hitting the limit-down, Huayuan Holdings touching the limit-down, and Greenland Holdings, Heungkong Holdings, China Vanke, and Risesun Development quickly following lower.
0811-OL.HK · Capital · Positive Xinhua Winshare announced plans to acquire 100% of Sichuan Nationalities Publishing House for 346 million yuan, a related-party acquisition.
601811.CG · Capital · Positive Same company as Xinhua Winshare; its announced 346 million yuan acquisition of Sichuan Nationalities Publishing House is the news driving the fifth consecutive limit-up.
Sichuan Minzu Publishing House Co Ltd · Capital · Positive Xinhua Winshare plans to acquire 100% of Sichuan Nationalities Publishing House for 346 million yuan from its controlling shareholder.
Sichuan Xinhua Publishing and Distribution Group · Capital · Positive As controlling shareholder, Sichuan Xinhua Publishing and Distribution Group is selling its 100% stake in Sichuan Nationalities Publishing House for 346 million yuan.
000710.CS · Regulation · Positive Berry Genomics hit the daily limit-up as the AI-driven drug discovery concept surged after the MIIT-led 15th Five-Year Plan for pharma explicitly backed AI in drug R&D.
300676.CS · Regulation · Positive BGI Genomics rose with the AI-driven drug discovery concept after the MIIT-led 15th Five-Year Plan called for accelerating AI use in drug R&D.
Xukang Gene Withdraws IPO Filing After Nearly Three Years and Eleven Tutoring Sessions
Shanghai Xukang Gene Technology Co., Ltd. has withdrawn its IPO tutoring filing, ending its listing process after nearly three years of tutoring and eleven progress reports. Xukang Gene signed a listing tutoring agreement with Huatai United Securities on November 24, 2023, and had completed eleven tutoring sessions as of July 2026. The final two tutoring progress reports since 2026 show the company still has shortcomings in internal controls and compliance awareness among directors, supervisors, and senior management. Industry insiders believe that a genetic testing pharmaceutical company voluntarily exiting its IPO most likely reflects that its business model sustainability and profitability still need to be strengthened. Xukang Gene's listing difficulties are not an isolated case. Companies such as Shihui Gene, Annoroad, and Zhenhe Technology have also repeatedly stumbled on their listing paths. Since 2026, two other in vitro diagnostics-related companies, Tianjin Bioaosais Biotechnology Co., Ltd. and Dajia Medical Laboratory Co., Ltd., have also withdrawn their IPO tutoring filings. At the industry level, China's genetic testing market reached approximately 48.7 billion yuan in 2025, with a compound annual growth rate exceeding 30%, and is expected to surpass 100 billion yuan by 2030. However, BGI Genomics posted a net loss attributable to shareholders of 617 million yuan in 2025, Berry Genomics has been loss-making for three consecutive years, and Rightongene has been loss-making for a second consecutive year, leaving the industry overall in a pattern of rising revenue without rising profits.
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▼Capital
Shanghai Xukang Gene Technology Co., Ltd. (序康基因) · Capital · Negative Withdrew its IPO tutoring filing after nearly three years, with shortcomings in internal controls and compliance and doubts over business-model sustainability.
300676.CS · Capital · Negative Reported a 617 million yuan net loss in 2025, exemplifying the industry's rising revenue without rising profits.
000710.CS · Capital · Negative Cited as loss-making for three consecutive years amid the genetic-testing industry's profitability struggles.
688217.CG · Capital · Negative Cited as loss-making for a second consecutive year, illustrating the industry's rising-revenue-without-profits pattern.
Berry Genomics reports net loss of 43.9479 million yuan in 2026 interim report
Berry Genomics released its 2026 interim report, with net profit attributable to the parent company at negative 43.9479 million yuan, a loss expansion of 16.7053 million yuan compared with the same period last year. The company's total operating revenue was 447 million yuan, down 0.15% year-on-year; net cash outflow from operating activities was 102 million yuan. The latest asset-liability ratio was 32.76%, gross margin was 50.53%, ROE was negative 3.09%, and diluted earnings per share was negative 0.12 yuan.
Berry Genomics reports first-half net loss attributable to shareholders of about 43.95 million yuan
Berry Genomics released its 2026 semi-annual report, showing a net loss attributable to shareholders of about 43.95 million yuan in the first half, a year-on-year decline of 61.32%. The company achieved operating revenue of about 447 million yuan over the same period, down 0.15% year on year. Berry Genomics said the loss was mainly due to an increase in provisions for bad debts on accounts receivable and higher research and development expenses, with increased depreciation of R&D equipment and related spending driving overall R&D expense growth.
000710.CS · Capital · Negative Net loss attributable to shareholders of 43.95 million yuan, down 61.32% year-on-year, due to higher bad debt provisions and R&D expenses.
Berry Genomics' Hou Ying to Auction 400,000 Shares Starting September 10
A total of 400,000 shares held by Hou Ying, a person acting in concert with the controlling shareholder of Berry Genomics, will be sold through judicial auction, representing 100% of her holdings and 0.11% of the company's total share capital. The auction time has been changed to run from 10 a.m. on September 10, 2026, until 10 a.m. on September 11. If the auction succeeds and the transfer is completed, Hou Ying will no longer hold any shares in the company and will cease to have a concert-party relationship with controlling shareholder Gao Yang. In the first quarter of 2026, Berry Genomics achieved revenue of 210 million yuan and a net loss attributable to the parent company of 19.74 million yuan.
000710.CS · Capital · Negative Controlling shareholder's concert party to auction all her shares, potentially altering control structure and adding uncertainty.
Berry Genomics concert party member Hou Ying's 400,000 shares to be auctioned, potentially leading to a complete exit
Berry Genomics announced that 400,000 shares held by Hou Ying, a concert party member of the controlling shareholder, will be subject to judicial auction. This represents 100% of her personal holdings and 0.11% of the company's total share capital. The auction stems from a dispute between Hou Ying and Hebei Financial Leasing over a finance lease contract, with the Shijiazhuang Intermediate People's Court ordering the sale of the shares. Previously, Hou Ying's shares had been auctioned multiple times due to a pledge dispute with Guosen Securities. As of July 2025, a cumulative 19.8057 million shares had been auctioned, with total transaction proceeds exceeding 214 million yuan, leaving only these 400,000 shares remaining for sale. If this auction succeeds, Hou Ying's shareholding will be reduced to zero, and her concert party relationship with the actual controller Gao Yang will automatically terminate. Some shares held by the company's actual controller Gao Yang have also been subject to judicial auction. If all transfers are completed, the company faces the risk of a change in controlling shareholder and actual controller. Berry Genomics has recorded losses for five consecutive years since 2021, with cumulative losses approaching 1.2 billion yuan. In the first quarter of 2026, revenue fell 3.46% year-on-year, and the net loss attributable to the parent company was 19.7382 million yuan.
000710.CS · Capital · Negative Judicial auction of Hou Ying's remaining shares may lead to loss of concert party status and potential change in control, amid ongoing losses.
Berry Genomics Projects First-Half 2026 Loss of 38 Million to 56 Million Yuan
Berry Genomics disclosed its earnings forecast, projecting a net loss attributable to shareholders of 38 million to 56 million yuan for the first half of 2026, compared with a loss of 27.2425 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 37 million to 55 million yuan, versus a loss of 28.5895 million yuan a year earlier. The company attributed the performance change mainly to industry cyclical fluctuations and intensified market competition, along with an increase in bad debt provisions for accounts receivable and slight rises in selling, administrative, and research and development expenses. The company continues to increase R&D investment, advancing multiple research projects, which has driven up overall R&D expenses. Non-recurring gains and losses are estimated at about 1 million yuan, primarily from gains on disposal of fixed assets and government subsidies.
China